WHAT IS KNOWN ABOUT THE ACTION OF DIHYDROERGOTAMINE ON THE VASCULATURE IN MAN
- 1 January 1984
- journal article
- research article
- Vol. 22 (12) , 677-682
Abstract
The vasoconstrictor activity of dihydroergotamine is long-lasting and independent from continuously elevated plasma levels. Dihydroergotamine evidently accumulates at the vascular smooth muscle cells and elicits venoconstriction through both stimulation of 5-HT [5-hydroxytryptamine] receptors as well as sensitization of the venous smooth muscle to the constrictor activity of biogenic amines. In vivo, the vasoconstrictor activity of dihydroergotamine is probably modulated through vasoactive metabolites, i.e, the vasoconstrictor profile and efficacy obviously varies with the ratio of the parent drug and dihydroergotamine metabolites in plasma.This publication has 3 references indexed in Scilit:
- PHARMACOKINETICS OF DIHYDROERGOTAMINE IN HEALTHY-VOLUNTEERS AND IN NEUROLOGICAL PATIENTS AFTER A SINGLE INTRAVENOUS-INJECTION1981
- PHARMACOKINETICS OF DIHYDROERGOTAMINE IN BEAGLE1978
- Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic ApplicationPublished by Springer Nature ,1978